Preclinical study identified HSP60 as potential target for reducing resistance to cisplatin treatment of prostate cancer

An article from the lab of Dhyan Chandra describes the novel finding that inhibition of the mitochondrial HSP60 chaperone or decreasing its expression restores sensitivity cisplatin of tumors cells from castration-resistant prostate cancer (CRPC). For more information see the press release. I am glad and happy that our Hsp60(+/-) mouse model established by Jane Hvarregaard Christensen in 2010 could be used in the context of cancer research after being used for studies in neurodegeneration (spastic paraplegia) and type-2 diabetes (hypothalamic insulin signaling). Still a lot to learn on the roles and impact of this indispensable chaperone on cellular biology.....